‘Lianhua Qingwen, a recommended medicine for treating patients with mild COVID-19 symptoms, has been approved as a Chinese proprietary medicine by the Health Sciences Authority in Singapore. The designation means the product can be sold in the country as a medicine, the drug’s manufacturer said.’
Read here (GMP News, May 7, 2020)
